Recently, the team led by Professor John P. A. Ioannidis from Stanford University, the United States, in collaboration with Elsevier, has released the World's Top 2% Scientists 2026 list. Professor Zhang Junliang, Founder of our company, has been successfully selected for the Career-long Impact list. This honor represents high recognition from the international academic community for his research achievements and academic influence from years of dedicated work in the field of chiral catalysis.

The World's Top 2% Scientists list is a widely‑acknowledged international evaluation system for research impact. Based on the Scopus citation database, it applies multiple quantitative metrics including paper citation counts, H‑index, co‑author‑adjusted Hm‑index, and citations for single‑authored / first‑author papers. It selects scholars whose academic influence ranks among the top 2% out of nearly ten million researchers worldwide. The list consists of two categories: the Career‑long Impact list and the Single‑Year Impact list. The Career‑long Impact list evaluates scholars' long‑term academic accumulation and sustained influence from the start of their research careers, representing the comprehensive achievements of their lifelong scientific work. It covers 22 major subject categories and 174 sub‑research fields.

Professor Zhang Junliang has long focused on cutting‑edge chemistry fields such as chiral catalysis and asymmetric synthesis. He devotes himself to the design, development and industrial transformation of chiral ligands and metal catalysts. His inclusion in the Career‑long Impact category of the World's Top 2% Scientists 2026 list recognizes Professor Zhang Junliang’s decades‑long commitment to scientific research and industry‑university‑research transformation. It also serves as strong evidence of our company’s research capabilities. Going forward, drawing support from Professor Zhang Junliang’s research team, our company will continue to advance both fundamental research and industrial innovation. We will further deepen our efforts in the high‑end catalyst sector, strengthen core‑technology R&D, accelerate the market‑oriented translation of high‑end catalysts, and contribute to the high‑quality development of China’s fine chemical and biomedicine industries.